Blood Cancer

Biography

Martin Dyer is Professor of Haemato-Oncology and Honorary Consultant Physician at the Department of Haematology, University Hospitals Leicester since April 2001. He is also Director of the Ernest and Helen Scott Haematological Research Institute at University of Leicester since Jan 2014. He has a longstanding interest in the targeted therapy of leukaemia and lymphoma. He has been the lead investigator in the development of several targeted therapies using antibodies and small molecules, including specific BTK and BCL2 inhibitors. Most recently he has led the first-in-man study of the first selective BTK inhibitor, ONO/GS-4059. As an MRC Clinical Research Fellow in Cambridge in the 1980's, he was involved in the initial clinical evaluation of the CAMPATH-1 antibodies in patients with B-cell malignancies. Moving to the Institute of Cancer Research-Royal Marsden Hospital in 1990, he developed the inverse PCR method for cloning immunoglobulin translocations, leading to the identification of genes including BCL7, BCL9, BCL10 and CRLF2, among others. Scientifically, Prof. Dyer and his group currently studying the molecular genetics and proteomics of lymphoid malignancies, using functional analysis of novel genes associated with B-cell receptor signalling and apoptotic pathways to design new therapeutic approaches. A major aim of his group is the identification of mechanism-based synergistic combinations.

Research Interest

leukaemia and lymphoma,Cancer Research,molecular genetics and proteomics of lymphoid malignancies.